Herbimycin A, a benzoquinoid
ansamycin antibiotic, was demonstrated to decrease intracellular phosphorylation by
protein tyrosine kinase (PTK). In
Philadelphia chromosome (Ph1)-positive
leukemias such as
chronic myelogenous leukemia (CML) and Ph1-positive
acute lymphoblastic leukemia (ALL), both of which express bcr-abl fused gene products (P210bcr-abl or P190bcr-abl
protein kinase) with augmented
tyrosine kinase activities,
herbimycin A markedly inhibited the in vitro growth of the Ph1-positive ALL cells and the leukemic cells derived from CML
blast crisis. However, the same dose of
herbimycin A did not inhibit in vitro growth of a broad spectrum of Ph1-negative human
leukemia cells, and several other
protein kinase antagonists also displayed no preferential inhibition. Furthermore, we demonstrated that
herbimycin A has an antagonizing effect on the growth of transformed cells by a transfection of retroviral amphotrophic vector expressing P210bcr/abl into a murine
interleukin (IL)-3-dependent myeloid FDC-P2 cell line. This inhibition was abrogated by the addition of
sulfhydryl compounds, similar to the reaction previously described for Rous sarcoma virus transformation. The inhibitory effect of
herbimycin A on the growth of Ph1-positive cells was associated with decreased
bcr/abl tyrosine kinase activity, but no decrease of bcr-abl
mRNA and
protein, suggesting that the inactivation of
bcr-abl tyrosine kinase activity by
herbimycin A may be induced by its binding to the bcr-abl
protein portion that is rich with sulfhydryl groups. The present study indicates that
herbimycin A is a beneficial agent for the investigation of the role of the bcr-abl gene in Ph1-positive
leukemias and further suggests that the development of agents inhibiting the bcr-abl gene product may offer a new therapeutic potential for Ph1-positive
leukemias.